

# An Introduction to Current Topics in Biology

## Topic 4: Microbiology & Infectious Disease

Dr Ruth Grady  
(sign into BoB for video)



# Content


- Microbes and infectious diseases
  - General concepts of infectious disease
  - Emerging and re-emerging infectious diseases
  - Antibiotics & phage therapy
- Antibiotic resistance; sexually transmitted diseases
- Discussion paper: Gut microbiome and faecal transplants

# Microorganisms

- Viruses (nm or  $10^{-9}$  m range)
  - Genetic elements that replicate *inside* cells
  - ‘sub-cellular parasites’
  - Consist of nucleic acid surrounded by protein
  - Classified by type of nucleic acid/how replicate/ single or double-stranded
- Bacteria ( $\mu\text{m}$  or  $10^{-6}$  m range)
  - Single-celled **prokaryotic** microorganisms
  - No membrane-bound nucleus

# What are microbes?

- <https://www.youtube.com/watch?v=h0xTKxbIEIU>




Too slow to play in class but worth a view (2 min 20 s)

What do microbiologists worry about today?




## Timeline of new and emerging infections since 1998



Images taken from the CDC Public Health Image Library: <https://phil.cdc.gov>

# Future?

## New infectious diseases since 1980



# Emerging and re-emerging infectious diseases today

- Old diseases now known to be microbiological
  - e.g. stomach ulcers (*Helicobacter pylori*);
- An old infection (re-) emerging because it has become resistant to treatment
  - e.g. XDR-TB (extensively drug-resistant TB)
  - Hospital-acquired infection
- Diseases (th)ought to have been eradicated but now re-emerged e.g. Syphilis; Chlamydia
- A recognised infection spreading to new populations (e.g. Zika /Ebola) or appearing in new areas
- A new infection resulting from changes in existing microorganisms
  - e.g. Bird/swine flu; SARS
- Discovering new tricks & roles for bacteria – role of gut bacteria in health and disease ?





# Emerging and re-emerging infectious diseases today

- Old diseases now known to be microbiological
  - e.g. stomach ulcers (*Helicobacter pylori*); cancer (HPV); Multiple sclerosis (EBV)
- An old infection (re-) emerging because it has become resistant to treatment
  - e.g. XDR-TB (extensively drug-resistant TB)
  - Hospital-acquired infection
- Diseases thought to have been eradicated but now re-emerged e.g. Syphilis; Chlamydia
- A recognised infection spreading to new populations (e.g. Zika /Ebola) or appearing in new areas
- A new infection resulting from changes in existing microorganisms
  - e.g. Bird/swine flu; SARS
- Discovering new tricks & roles for bacteria – role of gut bacteria in health and disease ?


# Antibiotics

How do antibiotics work?




## How do Antibiotics work?




- Inhibit cell wall formation (penicillin)
- Inhibit protein synthesis (tetracycline; erythromycin)
- Several other mechanisms...
- ...




### Gram Positive




### Gram Negative



# Use of antibiotics and resistance







PRECLINICAL	PHASE I	PHASE II	PHASE III	PHASE IV
Laboratory Research determines if treatment is useful and safe	6-10 Participants Understand effects of treatment in humans	20-50 Participants Evaluate safety and efficacy of treatment	100-200 Participants Confirm benefit and safety of treatment	200+ Participants Evaluate long-term effects of treatment

Why is investing in new antibiotics not attractive commercially?

Evolution of the total antibiotic pipeline and the antibiotic pipeline by stage of development, which includes: Clinical Trials ranging from Phase I, to evaluate safety; Phase II, to access effectiveness and safety; Phase III, to gather statistically significant data on safety, effectiveness and benefits-versus-risk; submission of a New Drug Application, for marketing approval; and lastly, Phase IV for post-marketing surveillance.


**Ribeiro da Cunha B, Fonseca LP, Calado CRC. Antibiotic Discovery: Where Have We Come from, Where Do We Go? Antibiotics (Basel) 2019; 8(2):45.**

# Mechanisms of antibiotic resistance

Drug Impermeability  
(innate)

Drug Efflux

Target modification



Drug Inactivation

Target bypass

- One type of antibiotic can be overcome by different mechanisms
- Different classes of antibiotics can have the same mechanisms of resistance
- Need to find new targets?

# Why does antibiotic resistance arise?

- Bacteria acquire genes from other bacteria (horizontal transfer of plasmid DNA)
- Bacteria grow quickly and mutations can arise v. quickly
  - Eg. Bacteria can repurpose structures to remove antibiotics
- Overuse of antibiotics
  - ‘over the counter’
- Animal husbandry
- Stopping antibiotics too soon
  - Not finishing a dose





# New approaches?

Historical:

- Natural compounds
- Semi-synthetic / synthetic

Genetic era:

- Genome analysis – find homologues / likely candidate genes

Post-genome era:

- Screening libraries of older compounds
- Systems biology

Other alternatives

- Targeting signalling messengers ('quorum sensing') between bacteria
- Phage therapy

# Quorum Sensing

Bacteria communicate with each other to alter behaviour


<https://learningonscreen.ac.uk/ondemand/index.php/clip/231194>

(transcript on notes under slide)

# ‘Cross-talk’ (communication) between bacteria and with host?

Allows ‘cross-talk’ (communication) between species and with host

- Via small signalling molecules
- ‘autoinducers’
  - Small proteins (oligopeptides) or RNA molecules
- Bind to receptors on /in bacterial cells which alters gene expression
  - Eg bacteria produce toxins or switch off flagella (movement) or bioluminescence



## New mechanism to control bacterial growth

- Quorum quenching:
- Interfering with QS signals; bacteria can survive, but not thrive?
- Reduction in antibiotic resistance?

# Resources

- UK Health Security Agency. UK website. Available from: [Health protection: Infectious diseases - detailed information - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/collections/health-protection-infectious-diseases)
  - Information regarding microbial pathogens, surveillance and characterisation of important pathogens. Produces weekly and monthly bulletins outlining current outbreaks
- Centers for Disease Control and Prevention (USA): <http://www.cdc.gov>
  - American version of above (note – the clinical guidance may not be the same as in UK but the information is !)

## **Microbiology Society** : [Homepage | Microbiology Society](https://www.microbiosociety.org/)


- A good website for topical microbiological stories (press releases and policy consultation responses)
- Hanssen, N.M., de Vos, W.M. and Nieuwdorp, M., 2021. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a bright future?. *Cell Metabolism*, 33(6), pp.1098-1110.

# Topic 4: Microbiology and Infectious Disease

Lecture 2: Phage therapy; antibiotic resistance and sexually-transmitted diseases

# Bacteriophage therapy?

- Viruses that infect bacteria: lytic/lysogeny (dormancy)
- Estimated  $10^{31}$  in total on earth!
- Discovered 1915 & 1917 independently
- Highly specific to a strain of bacteria species
  - Killed bacteria; used in 1930s
  - Properties were often 'oversold'
  - Lack of efficacy
  - Superseded by antibiotics
- In 'West': 'phages studied for Mol. Biol. Research
- In Soviet bloc – cocktails of phage preparations
- Antibiotic resistance – make phages look v attractive!



# Issues with 'phage therapy

- Phages are immunogenic
  - Cleared from blood; localised use only?
- FDA licensing granted in 2006 for food processing
  - Against food-poisoning bacteria (*Listeria*)
  - Disinfectant spray on animal feed
    - 'GRAS' licensing
- Human use?
  - 2007: Small-scale studies against ear infections
  - Fully sequenced phages: leg ulcers
  - *E. coli* diarrhoeal disease (Bangladesh)
  - 2012: burns victims (military)
  - 'Compassionate use': allowed when antibiotics have failed



# Pros and Cons


- Low dosing levels/ biofilm disruption
  - Multiply in hosts; then cleared naturally
  - Few side effects?
- Can avoid killing normal microflora
- Use of cocktails – less resistance?
- Know little about their biology
- Latency? Need to select phages carefully
- Worry regarding release of toxins
- Strain variation among clinical isolates
- Resistance?
- IP/patent issues – follow the money!

An old infection (re-) emerging because it has  
become resistant to treatment

# Healthcare-associated (nosocomial) infections

- Hospital-acquired/ healthcare-associated/ nosocomial, HAIs
- Not all HCAI are preventable
  - micro-organisms carried by the patient
  - Immuno-compromised patients
- Problem bacteria:
  - Met(h)icillin-resistant *Staphylococcus aureus* (MRSA a.k.a. ‘Superbug’)






# MRSA



- *Staphylococcus aureus*
  - skin & throat commensal
  - boils & carbuncles
- Methicillin-resistant *Staphylococcus aureus*
- 1961 first report of MRSA
- Became a major nosocomial problem
  - community issue too?
- At its peak: approx. 7000 new cases of MRSA blood infections per year; now approx. 700 (incl. HAI and community)

# Numbers of MRSA bacteraemia (Year 2007/08 to FY 2021/22)




Public Health England: Summary of the Mandatory Surveillance Annual Epidemiological Commentary, 2020/21

# Other important nosocomial bacteria

- *Pseudomonas aeruginosa*
  - Lung infections (esp. in cystic fibrosis)
  - Naturally resistant to many antibiotics
  - Grows as a biofilm
- *Clostridioides (Clostridium) difficile*
  - Diarrhoeal infection predominantly in ill patients
  - Spores not killed by alcohol hand gel
  - Some antibiotic-resistance now seen
- Carbapenemase-Producing Enterobacteriaceae (CPE)
  - Commensal on skin and in the gut (approx. 25 % of healthy people)
  - Cause urine infections, wound infections, pneumonia and septicaemia
  - Resistant to many antibiotics

# Reports of *C. difficile* infection



# **Experimental treatment: faecal microbiota transplants**

Hanssen, N.M., de Vos, W.M. and Nieuwdorp, M., 2021. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a bright future? *Cell Metabolism*, 33(6), pp.1098-1110.

Transfer of microbes from a 'healthy' donor to a patient


- High success rate (85% cure) for chronic *C. diff* infections following faecal microbiota transplant (FMT) from healthy to ill patients
- Not defined as to what a healthy microbiome is
  - Maybe more than one? Maybe not the actual bacteria but their metabolites?
- Risks of transplanting
  - Transmit depression/ anxiety/ obesity?
- Ethical implications
  - Changes may affect the local community? (as microflora can pass on – informed consent?)
  - Can they be passed to offspring?



Diseases thought to have been eradicated but  
now re-emerged


# Sexually-transmitted Infections


- Chlamydia/ gonorrhoea ('the clap')/ syphilis/ HIV/ herpes/



Percentages do not add up to 100% due to rounding


NB  
Chlamydia – most commonly  
diagnosed sexually-transmitted  
infection approx. 200 000 cases in  
2022





New diagnoses of syphilis (primary, secondary and early latent) 2013 – 2022, England.

In 2022, 8195 new diagnoses for all in England: highest since 1948 (743 in women)



New diagnoses of gonorrhoea 2013 – 2022, England.

NB

Chlamydia – most commonly diagnosed sexually-transmitted infection > 200 000 cases in 2021

# Chlamydia vs Gonorrhoea

## *Chlamydia trachomatis*

- Gram negative cocco/bacilli (2 morphologies)
- Hard to see in light microscope (very small!)
- Obligate intracellular bacteria
- Survives inside epithelial cells

## *Neisseria gonorrhoeae*

- Gram negative cocci
- Adhere (via pili and capsules) to epithelial cells of the urethra/cervix; multiply;
- Some cell invasion



# Chlamydia/ Gonorrhoea symptoms

Symptoms due to:

- Cell destruction/loss of function - discharge
- Host inflammatory response
- Often asymptomatic (Chl: 50% of men and 70-80% of women )

Chlamydia:

- Pain on urination, unusual discharge from the penis, vagina or rectum or, in women, bleeding between periods or after sex

Gonorrhoea:

- As above; usually thicker, copious yellow-green discharge
- Pelvic inflammatory disease or infertility or arthritis (mother)
- Untreated can lead to miscarriage, premature birth
- Eye infections (new-born)


# *N. gonorrhoeae* resistance

- In 2018 a heterosexual man in England was confirmed as having resistant N.g. (1<sup>st</sup> global report; acquired in Asia); 2 cases in Australia
  - Azithromycin (protein synthesis inhibitor)
  - Ceftriaxone (cell-wall inhibitor)
- Only susceptible to spectinomycin (protein synthesis inhibitor)

On the increase....

- 2015-2021: 9 cases detected in UK (all associated with international travel from Asia-Pacific area)
- First 6 months of 2022: 10 cases ..





# Syphilis




- Bacteria: *Treponema pallidum*
- Unusual shape and cell wall: 'spirochaetal'
- Hard to grow in the lab. (intracellular growth & anaerobic) and no animal model
  - Limited knowledge about mechanisms of pathogenicity
- Three (four) stages in infection process (distinct presentations)
  - Primary/ secondary/ (latent)/ tertiary



# Microbiologists and their toys ...



<https://www.giantmicrobes.com/uk/>




## Secondary hypersensitive rash

**Primary** chancre (painless!)




**Tertiary syphilis:** in approx. 15 % of people, develops years later after an untreated primary infection: neurological/systemic complications

## Number of syphilis (primary, secondary and early latent) diagnoses by sex in UK; 1922–2012



## UK Health Security Agency: Number of syphilis (primary, secondary and early latent) diagnoses by sex: England, 2012–2022



UK Health Security Agency: Sexually transmitted infections in England, 2022

# Next session: Discussion

Hanssen, N.M., de Vos, W.M. and Nieuwdorp, M., 2021. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a bright future?. *Cell Metabolism*, 33(6), pp.1098-1110.

Please read before you come to the session, and be prepared to share:

- a) 3 things that you didn't know before reading this paper
- b) the 3 things that interested you the most in the paper
- c) 3 things you didn't understand fully